TLR9 and metabolic dysfunction-associated steatohepatitis: Interestingly, mice and patients with NASH showed high plasma levels of EV-associated mitochondrial DNA, which could selectively upregulate TNF-α through activation of TLR9, while removal of these EVs or treatment with TLR9 antagonist blocked the development of NASH 139.